biotech / news / / The Manila Times
First ever successful wet AMD superiority trial comparing a novel investigative agent to an approved anti-VEGF.
AXPAXLI achieved the first successful superiority in a Phase 3 wet AMD trial over aflibercept.
KEY POINTS
- Ocular plans to submit an NDA for AXPAXLI using the 505(b)(2) pathway to potentially shorten review.
- SOL-R Phase 3 non-inferiority trial for wet AMD completed enrollment ahead of target, with data in 1Q 2027.
- The SOL-X extension trial began enrolling, assessing 3-year long-term safety and disease modification potential for AXPAXLI.
- Ocular's cash runway, at $666.7 million as of March 31, 2026, is expected to last into 2028.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →